+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk



Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk



Plos one 13(2): E0191817



Patient reports of their adherence behaviors, concerns about statins, and perceptions of atherosclerotic cardiovascular disease (ASCVD) risk could inform approaches for improving adherence to statin therapy. We examined these factors and their associations with adherence. We conducted telephone interviews among a stratified random sample of adults receiving statins within an integrated delivery system (N = 730, 81% response rate) in 2010. We sampled equal numbers of individuals in three clinical risk categories: those with 1) coronary artery disease; 2) diabetes or other ASCVD diagnosis; and 3) no diabetes or ASCVD diagnoses. We assessed 15 potential concerns about and barriers to taking statins, and perceived risk of having a heart attack in the next 10 years (0-10 scale). We calculated the proportion of days covered (PDC) by statins in the last 12 months using dispensing data and used multivariate logistic regression to examine the characteristics associated with non-adherence (PDC<80%). Analyses were weighted for sampling proportions. Sixty-one percent of patients with PDC<50% reported not filling a new prescription, splitting or skipping statins, or stopping refilling statins in the last 12 months vs. 15% of those with PDC≥80% (p<0.05). The most commonly reported concerns about statins were preferring to lower cholesterol with lifestyle changes (66%), disliking medications in general (59%), and liver or kidney problems (31%); having trouble remembering to take statins (9%) was the most common reason for taking less than prescribed. In multivariate analyses, clinical risk categories were not significantly associated with odds of non-adherence; however, those with higher perceived risk of heart attack were less likely to be non-adherent. Patient-reported medication-taking behaviors were correlated with statin PDC and those with lower perceived cardiovascular risk were less likely to be adherent. These findings highlight the importance of eliciting from and educating patients on their adherence behaviors and ASCVD risks.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065391454

Download citation: RISBibTeXText

PMID: 29420613

DOI: 10.1371/journal.pone.0191817


Related references

Patient-reported medication adherence barriers among patients with cardiovascular risk factors. Journal of Managed Care and Specialty Pharmacy 21(6): 479-485, 2015

A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the world health organization multidimensional adherence model. Journal of Clinical Hypertension 14(12): 877-886, 2012

Statin adherence and risk of acute cardiovascular events among women: a cohort study accounting for time-dependent confounding affected by previous adherence. Bmj Open 6(6): E011306, 2016

Associations between patients' adherence and GPs' attitudes towards risk, statin therapy and management of non-adherence--a survey and register-based study. Family Practice 33(2): 140-147, 2016

Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. Bmc Family Practice 10: 48, 2009

Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. European Journal of Clinical Pharmacology 64(4): 425-432, 2008

Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. Plos Medicine 13(11): E1002183, 2016

Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addiction Science and Clinical Practice 14(1): 11, 2019

Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors. American Journal of Clinical Oncology 41(5): 508-512, 2018

Discrepancy between patient-reported adherence and pharmacist-assessed adherence to antiretroviral therapy in patients with human immunodeficiency virus infection. Pharmacotherapy 20(10): 1246, 2000

Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. Journal of Personalized Medicine 4(2): 147-162, 2014

Examining prescriber perceptions of statin therapy and the potential implications these perceptions may have on guideline adherence. International Clinical Psychopharmacology 33(5): 290-296, 2018

Barriers to antiretroviral therapy adherence in developed countries: a qualitative synthesis to develop a conceptual framework for a new patient-reported outcome measure. Aids Care 30(Sup1): 17-28, 2018

Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study. Aids Research and Human Retroviruses 23(10): 1166-1175, 2007

Prior medication adherence of participants and non participants of a randomized controlled trial to improve patient adherence in cardiovascular risk management. Bmc Medical Research Methodology 19(1): 95, 2019